Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (6): 1083-1087. doi: 10.19723/j.issn.1671-167X.2021.06.013

Previous Articles     Next Articles

Serum interleukin-2 receptor α as a clinical biomarker in patients with systemic lupus erythematosus

TIAN Jia-yi,ZHANG Xia(),CHENG Gong,LIU Qing-hong,WANG Shi-yang,HE Jing()   

  1. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
  • Received:2021-07-30 Online:2021-12-18 Published:2021-12-13
  • Contact: Xia ZHANG,Jing HE E-mail:haoxiamei@163.com;hejing1105@126.com
  • Supported by:
    Peking University People’s Hospital Research and Development Funds(RS2020-01);National Natural Science Foundation of China(81601417)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the clinical relevance of serum interleukin-2 receptor α (IL-2Rα) in patients with systemic lupus erythematosus (SLE). Methods: One hundred and seven SLE patients and 39 healthy controls with comparable age and gender were recruited at Peking University People’s Hospital from January 2019 to December 2020. Complete clinical data in 107 SLE patients at baseline and follow-up were collected. SLE disease activity index 2000 (SLEDAI-2K) was used to assess the disease activity of the SLE patients. The serum level of IL-2Rα in the SLE patients and healthy controls was measured using enzyme-linked immunosorbent assay (ELISA). The association between serum IL-2Rα and clinical and laboratory parameters was investigated. Mann-Whitney U test or t test, Chi-square test and Spearman correlation were used for statistical analysis. Results: The serum IL-2Rα levels were significantly higher in the SLE patients [830.82 (104.2-8 940.48) ng/L], compared with those in the healthy controls [505.1 (78.65-1 711.52) ng/L] (P<0.001). Association analysis showed that the increased serum IL-2Rα was positively associated with SLEDAI-2K scores and anti-nucleosome antibody (r=0.357, P<0.001; r=0.25, P=0.027, respectively). Thirty-six of 107 (33.6%) SLE patients had lupus nephritis. Serum IL-2Rα levels were significantly higher in the patients accompanied with lupus nephritis [1 102.14 (126.52-8 940.48) ng/L] than in the patients without lupus nephritis [743.89 (104.19-4 872.06) ng/L] (P=0.032). The patients in the high IL-2Rα group had more lupus nephritis compared with those in the low IL-2Rα group (40.8% vs. 19.4%, P=0.031). Meanwhile, SLEDAI-2K scores were found significantly higher in the high IL-2Rα group than in the low IL-2Rα group [10 (3-21) vs. 7 (3-16), P=0.001]. With the improvement of disease activity in the SLE patients after conventional treatments, serum levels of IL-2Rα [1 119.1 (372.25-2 608.86) ng/L] in the week 12 decreased significantly compared with the baseline [1 556.73 (373.08-8 940.48) ng/L] (P=0.042). Conclusion: Serum IL-2Rα may be used as a biomarker of disease activity in patients with SLE. There is certain correlation between serum IL-2Rα and renal involvement in SLE.

Key words: Receptor, interleukin-2, Lupus erythematosus, systemic, Lupus nephritis, T-lymphocytes

CLC Number: 

  • R593.24

Figure 1

Correlation between serum IL-2Rα level and clinical significance IL-2Rα, interleukin-2 receptor α; SLE, systemic lupus erythematosus; SLEDAI-2K, SLE disease activity index 2000; AnuA, anti-nucleosome antibo-dy; LN, lupus nephritis. A, serum IL-2Rα level in SLE group was significantly higher than that in control group; B, serum IL-2Rα level was positively correlated with SLEDAI-2K score; C, serum IL-2Rα level was positively correlated with AnuA titer; D, serum IL-2Rα levels in SLE patients with LN were significantly higher than those without LN."

Table 1

Comparison between high IL-2Rα group (≥590.48 ng/L) and low IL-2Rα group (<590.48 ng/L)"

Items High IL-2Rα (n=71) Low IL-2Rα (n=36) P value
Gender,Female/Male 6/65 1/35 0.419
Age/year, median (range) 31 (18-66) 36 (29-52) 0.741
Duration/year, median (range) 2.0 (0.1-23.0) 2.0 (0.2-12.0) 0.355
LN, n (%) 29 (40.8) 7 (19.4) 0.031
SLEDAI-2K, median (range) 10 (3-21) 7 (3-16) 0.001
IgG/(g/L), median (range) 13.7 (1.9-35.9) 16.55 (8.2-29.9) 0.862
C3/(g/L), median (range) 0.453 (0.118-1.46) 0.656 (0.239-0.821) 0.685
C4/(g/L), median (range) 0.117 (0.04-0.544) 0.097 (0.032-0.227) 0.627
Anti-dsDNA/(IU/mL), median (range) 223.98 (25-1 845.6) 277.12 (20-1 665.8) 0.375
AnuA/(IU/mL), median (range) 133.87 (2-1 918.3) 85.72 (2-1 991.9) 0.197
ESR/(mm/h), median (range) 31 (6-110) 40 (11-42) 0.786
CRP/(mg/dL), median (range) 4.65 (1.05-93.2) 2.49 (1.03-10.8) 0.952

Figure 2

Changes of serum IL-2Rα level and SLEDAI-2K before and after treatment in SLE Abbreviations as in Figure 1. A, the serum IL-2Rα level in SLE patients decreased significantly after 12 weeks; B, SLEDAI-2K improved significantly after 12 weeks."

[1] Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus[J]. Nat Immunol, 2020, 21(6):605-614.
doi: 10.1038/s41590-020-0677-6
[2] Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes[J]. Annu Rev Immunol, 2018, 36:411-433.
doi: 10.1146/immunol.2018.36.issue-1
[3] He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(1):141-149.
[4] He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J]. Nat Med, 2016, 22(9):991-993.
doi: 10.1038/nm.4148
[5] Rubin L A, Galli F, Greene WC, et al. The molecular basis for the generation of the human soluble interleukin 2 receptor[J]. Cytokine, 1990, 2(5):330-336.
pmid: 2103332
[6] Dik WA, Heron M. Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases[J]. Neth J Med, 2020, 78(5):220-231.
[7] Luo H, Wang C, Feng M, et al. Microgravity inhibits resting T cell immunity in an exposure time-dependent manner[J]. Int J Med Sci, 2014, 11(1):87-96.
doi: 10.7150/ijms.7651
[8] El-Shafey EM, El-Nagar GF, El-Bendary AS, et al. Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus[J]. Iran J Kidney Dis, 2008, 2(2):80-85.
pmid: 19377213
[9] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9):1725.
[10] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000[J]. J Rheumatol, 2002, 29(2):288-291.
pmid: 11838846
[11] Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: Updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)[J]. Arthritis Care Res (Hoboken), 2011, 63(Suppl 11):S37-S46.
doi: 10.1002/acr.v63.11s
[12] Russell SE, Moore AC, Fallon PG, et al. Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice[J]. PLoS One, 2012, 7(10):e47748.
doi: 10.1371/journal.pone.0047748
[13] Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: From molecular mechanisms to human therapy[J]. Nat Rev Immunol, 2018, 18(10):648-659.
[14] Mizui M, Tsokos GC. Targeting regulatory T cells to treat patients with systemic lupus erythematosus[J]. Front Immunol, 2018(9):786.
[15] Laut J, Senitzer D, Petrucci R, et al. Soluble interleukin-2 receptor levels in lupus nephritis[J]. Clin Nephrol, 1992, 38(4):179-184.
pmid: 1424303
[1] Jiang JIN, Xue CHEN, Yan ZHAO, Jun JIA, Jianzhong ZHANG. The role and its regulatory significance of interleukin-25 in ovalbumin induced atopic dermatitis of mice [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 756-762.
[2] Ying TANG, Yongbo ZHANG, Danhong WU, Yanhong LIN, Fenghua LAN. Detection of pathogenic gene mutations in thirteen cases of congenital bilateral absence of vas deferens infertility patients [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 763-774.
[3] Zhihui WU, Mingzhi HU, Qiaoying ZHAO, Fengfeng LV, Jingying ZHANG, Wei ZHANG, Yongfu WANG, Xiaolin SUN, Hui WANG. Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 860-867.
[4] Xiaodong CHAI,Ziwen SUN,Haishuang LI,Liangyi ZHU,Xiaodan LIU,Yantao LIU,Fei PEI,Qing CHANG. Clinicopathological characteristics of the CD8+ T lymphocytes infiltration and its mechanism in distinct molecular subtype of medulloblastoma [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 512-518.
[5] Limin REN,Chuchu ZHAO,Yi ZHAO,Huiqiong ZHOU,Liyun ZHANG,Youlian WANG,Lingxun SHEN,Wenqiang FAN,Yang LI,Xiaomei LI,Jibo WANG,Yongjing CHENG,Jiajing PENG,Xiaozhen ZHAO,Miao SHAO,Ru Li. Low disease activity and remission status of systemic lupus erythematosus in a real-world study [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 273-278.
[6] Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027.
[7] Zhi-jun LUO,Jia-jia WU,You SONG,Chun-li MEI,Rong DU. Systemic lupus erythematosus associated macrophage activation syndrome with neuropsychiatric symptoms: A report of 2 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1111-1117.
[8] Hai-hong YAO,Fan YANG,Su-mei TANG,Xia ZHANG,Jing HE,Yuan JIA. Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 966-974.
[9] Xiang-ge ZHAO,Jia-qing LIU,Hui-na HUANG,Zhi-min LU,Zi-ran BAI,Xia LI,Jing-jing QI. Interferon-α mediating the functional damage of CD56dimCD57+natural killer cells in peripheral blood of systemic lupus erythematosuss [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 975-981.
[10] Zhuo-hua LIN,Ru-yi CAI,Yang SUN,Rong MU,Li-gang CUI. Methodology and clinical use of superb microvascular imaging in assessing micro-circulation changes of fingertips in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 636-640.
[11] Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253.
[12] Fang CHENG,Shao-ying YANG,Xing-xing FANG,Xuan WANG,Fu-tao ZHAO. Role of the CCL28-CCR10 pathway in monocyte migration in rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1074-1078.
[13] Lu ZHANG,Cheng CHEN,Mei-ting WENG,Ai-ping ZHENG,Mei-ling SU,Qing-wen WANG,Yue-ming CAI. Characteristics of serum autoantibodies in patients with lupus nephritis and tubulointerstitial damage [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1094-1098.
[14] Lin-qi ZHANG,Jing ZHAO,Hong-yan WANG,Zong-yi WANG,Ying-ni LI,Ji-yang TANG,Si-ying LI,Jin-feng QU,Ming-wei ZHAO. Relationship between anti-ENO1 antibody and systemic lupus erythematosus patients with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1099-1105.
[15] Min LI,Lin-qing HOU,Yue-bo JIN,Jing HE. Clinical and immunological characteristics of systemic lupus erythematosus with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1106-1111.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd